Barclays
TARS icon

Barclays’s Tarsus Pharmaceuticals TARS Stock Holding History

Barclays’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,700
Closed -$755K – 5673
2025
Q3 		$755K Buy
+12,700
New +$625K ﹤0.01% 3539

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's TARS Position: Q1 2026 in Review

Barclays reduced its Tarsus Pharmaceuticals (TARS) stake by 65% in Q1 2026, selling an estimated $3.69M and leaving 28,004 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

Barclays first reported a position in TARS in Q1 2022 and has held it in 17 quarters since. The position peaked at $6.61M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Barclays held 28,004 shares of Tarsus Pharmaceuticals worth $1.96M as of Q1 2026.
  • Barclays sold 52,780 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $3.69M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2365 holding.
  • Barclays first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Tarsus Pharmaceuticals position peaked at $6.61M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.